Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02696096
Other study ID # 793387
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date August 2016
Est. completion date February 2020

Study information

Verified date July 2022
Source Butler Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study proposes to use functional magnetic resonance imaging (FMRI) to observe brain activity and behavior associated with decision-making about rewards (DD task), working memory and working memory cognitive persistence (WM task), and craving (CR task) in 72 opiate dependent participants initiating buprenorphine. While stably using opiates (initial study appointment) and again during withdrawal (approximately 3 days later), participants will receive an FMRI scan with behavioral challenges; immediately after the second FMRI, they will receive their first dose of buprenorphine. Buprenorphine treatment will continue for twelve weeks, followed by a four week taper. Urine toxicological analysis will be performed prior to the first scanning session, weekly for two weeks and biweekly thereafter. Participation for all individuals will last 4 months. Assessments will occur at baseline, and weeks 1, 2, 4, 8, and 12. Buprenorphine induction will begin at the completion of the second scan; follow-up medical visits will align with study assessments on weeks 1, 2, 4, 8 and 12. All participants will receive 16 weeks of buprenorphine (the final 4 of these 16 weeks will include a taper).


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date February 2020
Est. primary completion date February 2020
Accepts healthy volunteers No
Gender All
Age group 21 Years to 50 Years
Eligibility Inclusion Criteria: - opiate dependent persons - 21-50 years old - interested in initiating outpatient buprenorphine treatment Exclusion Criteria: - current methadone maintenance treatment program participation - medically necessary prescription opiate treatment (e.g., for chronic pain) - current criteria for a DSM-V diagnosis of substance dependence for sedative or hypnotic drugs, alcohol, stimulants, cocaine, inhalants, hallucinogens - diagnosis of organic brain disorder, bipolar disorder, schizophrenia, schizo-affective, schizophreniform or paranoid disorder - current suicidality on the Modified Scale for Suicidal Ideation - evidence of neuropsychological dysfunction as assessed by the study physician with confirmation with the Folstein Mini-Mental Status Examination• - anticipated major painful event (significant surgical procedure) in the coming 4 months - probation or parole requirements or an upcoming move that might interfere with protocol participation - history of allergic reaction to buprenorphine or naloxone - currently pregnant or planning to become pregnant in the next 4 months - history of neurological disorder (e.g., epilepsy, stroke, brain injury) - impaired uncorrected vision - FMRI contraindications (e.g., claustrophobia, specific metallic implants and injuries)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
FMRI
all participants will complete 2 FMRIs
Drug:
Suboxone
all participants will be prescribed Suboxone for 4 months during their study participation

Locations

Country Name City State
United States Butler Hospital Providence Rhode Island

Sponsors (1)

Lead Sponsor Collaborator
Butler Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in Resting State Disorganization Between Baseline and One Week by Person by Lapsed Category The measure of resting state organization is a z-value derived from Pearson's r-values. They represent the effect of the association between the brain activity of the seed region and each brain voxel over time during the resting state FMRI scan. A central z-value of 0 means that there is no association between the seed region and the voxel.
Positive and negative z-values approaching 0 reflect increasingly weaker associations, and more extreme positive and negative values reflect stronger associations. Attributing the qualitative labels better or worse to these values depend upon the brain network and context. In many networks (eg, task-positive cognitive control network), a stronger positive correlation is thought to reflect better network organization. In the task-negative default mode network a stronger positive relationship is considered by some as worse. For this study, these are not yet used as clinical measures and there are not known cutoffs.
Baseline and 1 week
Primary Working Memory - Between Groups at Baseline by Lapsed Category fMRI working memory differences between participants who lapse back to opioid use and those who don't Baseline
Primary Changes in Working Memory - Within Groups During Satiation and Withdrawal fMRI working memory differences under satiation vs withdrawal from opioids Baseline and 1 week
See also
  Status Clinical Trial Phase
Completed NCT04336293 - sTMS for Substance Use-disordered Veterans N/A
Completed NCT01188421 - Medications Development for Drug Abuse Disorders Phase 1/Phase 2
Completed NCT00499746 - The Discriminative Effects of Tramadol in Humans Phase 1/Phase 2
Not yet recruiting NCT05611749 - Duloxetine Impact on Postoperative Pain Control and Outcomes Phase 2
Recruiting NCT04325659 - An Innovative Intervention for OUD Treatment Phase 2/Phase 3
Completed NCT03685162 - Observational Study to Evaluate Levomethadone Safety and Effectiveness in Subjects Under Opioid Maintenance Treatment
Recruiting NCT04239235 - Integrating Support Persons Into Recovery N/A
Not yet recruiting NCT03394911 - Healthy Adult Male Facial Skin Surface Lipid Pheromone p.o. to Treat Opioid Addiction Phase 3
Not yet recruiting NCT02282072 - PINS Stimulator System for Deep Brain Stimulation of the Nucleus Accumbens to Treat Severe Opioid Addiction Phase 0
Not yet recruiting NCT01008072 - Ultra-rapid Opiate Detoxification Using Deep Sedation and Prior Oral Buprenorphine Preparation. N/A
Recruiting NCT05299515 - Peer Activate: Trial of Peer-Delivered Behavioral Activation for Methadone Adherence N/A
Recruiting NCT04309565 - Transitions Clinic Network: Post Incarceration Addiction Treatment, Healthcare, and Social Support N/A
Completed NCT01873989 - Testosterone Replacement for Male Opioid Agonist Maintained Patients Phase 1/Phase 2
Completed NCT01590251 - Yoga for Pain and Opioid Dependence Phase 1/Phase 2
Active, not recruiting NCT02866266 - ER/LA Opioid Surveillance for Emergency Department Visits and Hospitalizations for Overdose and Poisoning N/A
Enrolling by invitation NCT02871232 - Surveillance Monitoring of Opioid Abuse in Poison and Drug Treatment Centers N/A